Developing a germline prostate cancer risk test incorporating rare and common variants, to inform clinical decisions: a route to precision oncology.
- DOI
- 10.1186/s13073-026-01640-y
- Published
- 2026 Apr 18
- Container
- Genome medicine
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1186/s13073-026-01640-y,
title = {Developing a germline prostate cancer risk test incorporating rare and common variants, to inform clinical decisions: a route to precision oncology.},
author = {Wakerell S and Karlsson Q and Merson S and Rageevakumar R and Saunders E and Burns D and Brook MN and Dadaev T and Page EC and Thomas S and Taylor N and Pope J and Cousins S and McHugh J and Jones AB and McVeigh TP and Bancroft EK and Eeles RA and Kote-Jarai Z},
year = {2026},
journal = {Genome medicine},
doi = {10.1186/s13073-026-01640-y},
url = {https://doi.org/10.1186/s13073-026-01640-y}
}RIS
TY - JOUR TI - Developing a germline prostate cancer risk test incorporating rare and common variants, to inform clinical decisions: a route to precision oncology. AU - Wakerell S AU - Karlsson Q AU - Merson S AU - Rageevakumar R AU - Saunders E AU - Burns D AU - Brook MN AU - Dadaev T AU - Page EC AU - Thomas S AU - Taylor N AU - Pope J AU - Cousins S AU - McHugh J AU - Jones AB AU - McVeigh TP AU - Bancroft EK AU - Eeles RA AU - Kote-Jarai Z PY - 2026 JO - Genome medicine DO - 10.1186/s13073-026-01640-y UR - https://doi.org/10.1186/s13073-026-01640-y ER -
APA
S, W., Q, K., S, M., R, R., E, S., D, B., MN, B., T, D., EC, P., S, T., N, T., J, P., S, C., J, M., AB, J., TP, M., EK, B., RA, E., & Z, K. (2026). Developing a germline prostate cancer risk test incorporating rare and common variants, to inform clinical decisions: a route to precision oncology.. Genome medicine. https://doi.org/10.1186/s13073-026-01640-y
Source records
- pubmed · retrieved 2026-09-25T21:25:18.957Z